Exhibit 99.1
 
Palatin Technologies, Inc. Reports Second Quarter
 
Fiscal Year 2021 Financial Results and Recent Business Highlights
 
● 
Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease
 
 
Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi®
 
● 
Approximately $72.2 Million in Cash and Cash Equivalents at
 
December 31, 2020
 
 
Teleconference and Webcast to be held on February 17, 2021 at 11:00 AM ET
 
 
CRANBURY, NJ – February 17, 2021 – Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its second quarter ended December 31, 2020.
 
Second Quarter Ended December 31, 2020 Financial Highlights
 
Net loss for the quarter was $(10.0) million, or $(0.04) per share, compared to a net loss of $(5.2) million, or $(0.02) per share for the comparable quarter of 2019;
 
The increase in net loss was primarily attributable to commercial expenses related to Vyleesi and to PL9643’s Phase 2 study for the treatment of dry eye disease.
 
As of December 31, 2020, the Company had $72.2 million in cash and cash equivalents and $4.7 million in accounts receivable, compared to $82.9 million in cash and cash equivalents and no accounts receivable as of June 30, 2020, with no outstanding debt.
 
Business Highlights and Updates
 
Hypoactive Sexual Desire Disorder (HSDD) / Vyleesi® (bremelanotide injection)
 
Vyleesi gross sales for the quarter ended December 31, 2020 amounted to $943,950. Vyleesi product revenue was $(163,971), net of allowances and accruals. Vyleesi gross sales for the period July 25 to September 30 amounted to $809,100. Vyleesi product revenue was $(288,560), net of allowances and accruals;
 
Restructured the distribution network and procedures improving the patient experience; expanded contact with prescribers and healthcare providers through virtual meetings; increased insurance reimbursement coverage; and initiated a highly selective digital marketing and telemedicine campaign to rebuild awareness and demand among pre-menopausal women with a geo-targeting approach.
 
Anti-Inflammatory / Autoimmune Programs
 
Announced positive results in its Phase 2 study of PL9643 for the treatment of dry eye disease (DED);
 
Announced statistically significant improvements in multiple signs and symptoms in the moderate to severe patient population after 2 weeks of dosing and at the 12-week visit.
 
There were no safety signals identified and PL9643 had excellent ocular tolerability.
 
Statistical significance for the primary endpoints was not reached in the overall enrolled population that included mild, moderate, and severe patients, as measured at the 12-week primary evaluation visit.
 
A Phase 2/3 Clinical trial with PL9643 for the treatment of DED is currently planned for mid-calendar year 2021;
 
Filed an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides; and
 
A Phase 2 proof-of-concept clinical study with an oral formulation of PL8177 in ulcerative colitis patients is targeted to start mid-calendar year 2021, with data readout potentially in mid-calendar year 2022.
 
 
 
 
“Working through the melanocortin system, PL9643 is a novel approach to treating dry eye disease. The emerging profile of PL9643, with its rapid therapeutic onset and excellent tolerability profile, is a potentially distinct advance in dry eye therapy," stated Carl Spana, Ph.D., President and CEO of Palatin. "The positive PL9643 Phase 2 study results identify the most appropriate patient population, endpoints, and timepoints for the next study, which is a Phase 2/3 study targeted for mid-calendar year 2021, with data readout in the first half of calendar year 2022. Regarding Vyleesi, our measured plan and investment is showing positive trends and returns with a significant rise in payer reimbursement and double-digit increases to month over month prescription numbers continuing through January 2021.”
 
Conference Call / Webcast
 
Palatin will host a conference call and audio webcast on February 17, 2021 at 11:00 a.m. Eastern Time to discuss the quarter ended December 31, 2020 results of operations in greater detail and provide an update on corporate developments. Individuals interested in listening to the conference call live can dial 1-866-248-8441 (US/Canada) or 1-856-344-9206 (international), conference ID 2203098. The audio webcast and replay can be accessed by logging on to the “Investor/Webcasts” section of Palatin’s website at http://www.palatin.com. A telephone and audio webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (US/Canada) or 1-719-457-0820 (international), passcode 2203098. The webcast and telephone replay will be available through February 24, 2021.
 
About Palatin Technologies, Inc.
 
Palatin Technologies, Inc. is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.Palatin.com.
 
-More-
Exhibit 99.1
 
 
 
Forward-looking Statements
 
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about market potential of Palatin’s products, clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates, Palatin’s ability to manufacture and market Vyleesi, market potential for product candidates, and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, Palatin's ability to establish and maintain the capability for manufacturing, marketing and distribution of Vyleesi, sales of Vyleesi in the United States and elsewhere in the world, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.
 
 
Investor Inquiries:
Media Inquiries:
Stephen T. Wills, CPA, MST
Paul Arndt, MBA, LifeSci Advisors
CFO/COO (609) 495-2200
Managing Director (646) 597-6992
Info@Palatin.com
Paul@LifeSciAdvisors.com
 
 
 
Palatin Technologies® and Vyleesi® are registered trademarks of Palatin Technologies, Inc.
###
(Financial Statement Data Follows)
 
 
 
PALATIN TECHNOLOGIES, INC.
and Subsidiary
Consolidated Statements of Operations
(unaudited)
 
 
 
Three Months Ended December 31,
 
 
Six Months Ended December 31,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVENUES
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue, net
 $(163,971)
 $- 
 $(452,531)
 $- 
License and contract
  - 
  20,610 
  - 
  117,989 
 
  (163,971)
  20,610 
  (452,531)
  117,989 
OPERATING EXPENSES
    
    
    
    
    Cost of products sold
  29,400 
  - 
  54,600 
  - 
Research and development
  4,011,418 
  3,257,624 
  6,935,269 
  6,385,113 
Selling, general and administrative
  5,044,913 
  2,404,093 
  7,376,519 
  4,236,535 
Gain on license termination agreement
  - 
  - 
  (1,623,795)
  - 
Total operating expenses
  9,085,731 
  5,661,717 
  12,742,593 
  10,621,648 
 
    
    
    
    
Loss from operations
  (9,249,702)
  (5,641,107)
  (13,195,124)
  (10,503,659)
 
    
    
    
    
OTHER (EXPENSE) INCOME
    
    
    
    
Investment income
  4,800 
  399,982 
  16,935 
  770,636 
Foreign currency loss
  (745,002)
  - 
  (745,002)
  - 
Interest expense
  (1,871)
  (2,502)
  (9,360)
  (11,553)
Total other (expense) income, net
  (742,073)
  397,480 
  (737,427)
  759,083 
NET LOSS
 $(9,991,775)
 $(5,243,627)
 $(13,932,551)
 $(9,744,576)
 
    
    
    
    
 
    
    
    
    
Basic and diluted net loss per common share
 $(0.04)
 $(0.02)
 $(0.06)
 $(0.04)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share
  236,405,065 
  234,923,592 
  236,375,463 
  234,018,417 
 
 
 
 
PALATIN TECHNOLOGIES, INC .
and Subsidiary
Consolidated Balance Sheets
(unaudited)
 
 
 
December 31, 2020
 
 
June 30, 2020
 
ASSETS
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents
 $72,156,110 
 $82,852,270 
Accounts receivable
  4,746,623 
  - 
Inventories
  6,031,088 
  - 
Prepaid expenses and other current assets
  2,556,911 
  738,216 
Total current assets
  85,490,732 
  83,590,486 
 
    
    
Property and equipment, net
  116,362 
  140,216 
Right-of-use assets
  1,113,685 
  1,266,132 
Other assets
  56,916 
  56,916 
Total assets
 $86,777,695 
 $85,053,750 
 
    
    
LIABILITIES AND STOCKHOLDERS’ EQUITY
    
    
Current liabilities:
    
    
Accounts payable
 $1,174,493 
 $715,672 
Accrued expenses
  4,799,561 
  2,899,097 
Short-term operating lease liabilities
  265,339 
  312,784 
Other current liabilities
  1,010,250 
  - 
Total current liabilities
  7,249,643 
  3,927,553 
 
    
    
Long-term operating lease liabilities
  855,626 
  953,348 
Other long-term liabilities
  10,837,300 
  - 
Total liabilities
  18,942,569 
  4,880,901 
 
    
    
Stockholders’ equity:
    
    
 
Preferred stock of $0.01 par value – authorized 10,000,000 shares; shares issued and outstanding designated as follows:
 
Series A Convertible: authorized 264,000 shares: issued and outstanding 4,030 shares as of December 31, 2020 and June 30, 2020
  40 
  40 
Common stock of $0.01 par value – authorized 300,000,000 shares:
    
    
issued and outstanding 230,034,307 shares as of December 31, 2020 and 229,258,400 shares as of June 30, 2020
  2,300,343 
  2,292,584 
Additional paid-in capital
  397,666,196 
  396,079,127 
Accumulated deficit
  (332,131,453)
  (318,198,902)
Total stockholders’ equity
  67,835,126 
  80,172,849 
Total liabilities and stockholders’ equity
 $86,777,695 
 $85,053,750 
 
 
 

View differences made from one to another to evaluate Palatin Technologies Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Palatin Technologies Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account